Notably, synthetic lethality was demonstrated with BRCA1/2 alterations in ovarian cancer and inhibition of poly (ADP-ribose) polymerase 1 (PARP1; Figure 2) [65,66,67]. This evidence concerns the gene PARP1 and ovarian carcinoma.